Richard Hennings

Strategic Development Advisor

image

Novateur Advisor Since

2024

Field

Commercial Portfolio & Product Lifecycle Strategy & Execution, Respiratory, Anti-infectives, Anti-virals, Oncology, Rare Disease, Cns & Delivery Devices

Specialties

Business Development, Commercial Strategy & Operations, Corporate & Medical Affairs, Fundraising (Grants, Angels & Venture Capital), Partnering

"We bring deep cross-functional biopharma product development & commercialization experience, collaborating with innovative companies to realise the potential of patient life-changing treatments."

Richard Hennings
Strategic Development Advisor

Richard Hennings is C-suite biopharma entrepreneur with +30 years global experience, developing and commercializing innovative therapies. 
Richard has diverse organizational knowledge from roles within top ten global pharmaceuticals & microcap biotech start-ups.
He is an accomplished leader, building organisational capability through cross-functional team leadership & influential relationships with board of directors, joint venture partners and external patient/ medical associations. His experience spans early-stage portfolio strategy development, fundraising & commercial execution.
Richard recently served as Chief Commercial Officer at Synairgen, previously holding commercial leadership roles at Gilead, Novartis, AstraZeneca & Verona Pharma, where he supported a $200M Ph 3 fund raise for Ohtuvayre®. During his Gilead tenure Richard led the expansion of respiratory & anti-viral product portfolios in the EU & US markets, launching inhaled Cayston® for Cystic Fibrosis & HIV treatment Stribild®.

Novateur Newsletter

Subscribe to our newsletter for access to latest updates.

Resource Databases

Access Novateur news as well as FDA and Expert Databases.

Relevant Events

Check out conferences and events we are attending!